What is the appropriate first‑line treatment for an elderly patient with stage IV papillary urothelial carcinoma metastatic to bone, liver, and lung?

Frontline Treatment of Stage IV Papillary Urothelial Cancer in Elderly Patients

For elderly patients with stage IV papillary urothelial carcinoma with widespread metastases to bone, liver, and lung, enfortumab vedotin plus pembrolizumab (EV+P) is the preferred first-line treatment regardless of age, offering superior survival outcomes (median OS 31.5 months) compared to all other options. 1, 2

Treatment Algorithm Based on Patient Fitness

For Fit Elderly Patients (PS 0-1, adequate organ function):

Primary recommendation: Enfortumab vedotin + Pembrolizumab 1, 2

• Demonstrated remarkable survival benefit with HR 0.47 for overall survival versus platinum chemotherapy
• Objective response rate of 68% with 29% complete responses
• Age alone should NOT determine treatment selection 1
• Continue treatment until progression, requiring proactive management of adverse events

Key toxicities requiring monitoring:

• Skin reactions (grade ≥3 in 15.5%)
• Peripheral neuropathy (grade ≥3 in 6.8%)
• Hyperglycemia (grade ≥3 in 6.1%)
• Dose modifications needed in approximately 70% of elderly patients 3

Alternative for Cisplatin-Eligible Fit Elderly Patients:

Nivolumab + Gemcitabine/Cisplatin 1, 4

• Weak recommendation as alternative to EV+P
• Requires adequate renal function (GFR >60 mL/min)
• Consider only if EV+P unavailable or contraindicated

For Elderly Patients with Borderline Fitness (PS 1-2):

Carboplatin-based combination chemotherapy 1, 3

• Gemcitabine/carboplatin is the standard platinum option for cisplatin-ineligible patients
• Survival advantage demonstrated in patients aged 70-89 with PS 0-2 5, 6
• Real-world data shows 40% objective response rate but 76.7% grade ≥3 toxicity in octogenarians 3
• Median PFS 5.2 months, OS 11.3 months in patients ≥80 years 3

Critical caveat: Myelosuppression frequently necessitates dose reduction (70% of patients) or treatment discontinuation (46.7%) in octogenarians 3

For Frail Elderly Patients (PS 2-3):

Single-agent chemotherapy 5, 6

• Gemcitabine, vinorelbine, or taxanes as monotherapy
• Standard approach for clinically unselected or comorbid elderly patients
• Lower toxicity burden but reduced efficacy

PD-L1 inhibitor monotherapy (if PD-L1 positive):

• Pembrolizumab or atezolizumab for PD-L1-positive tumors 1
• Weak recommendation, reserved for platinum-ineligible patients
• Consider only if unable to tolerate combination therapy

Critical Decision Points

Cisplatin Eligibility Criteria (must meet ALL):

• GFR ≥60 mL/min
• ECOG PS 0-1
• No significant hearing loss
• No peripheral neuropathy ≥grade 2
• No heart failure NYHA class III

When NOT to Use EV+P:

• Severe pre-existing peripheral neuropathy
• Uncontrolled diabetes
• Limited social support for managing complex toxicities in very elderly patients 7
• Consider carboplatin-based therapy or single-agent approaches instead

Evidence Strength and Nuances

The 2025 EAU guidelines 1 represent the most current evidence, assigning strong recommendations to EV+P based on the EV-302 trial showing unprecedented survival benefit. This supersedes decades of platinum-based chemotherapy as standard of care.

Important divergence in evidence: While EV+P shows superior efficacy, real-world data in octogenarians 3 demonstrates that even carboplatin-based regimens require careful patient selection and proactive toxicity management. The 76.7% grade ≥3 toxicity rate in patients ≥80 years receiving platinum chemotherapy underscores that chronological age alone is insufficient—functional status, organ function, and social support are paramount.

Shared decision-making is essential 7 because the survival benefit of EV+P requires continued treatment through toxicities. In elderly patients with limited family support or multiple comorbidities, sequential therapy starting with carboplatin-based chemotherapy followed by maintenance avelumab may be more practical, despite lower initial efficacy.

Common Pitfalls to Avoid

1. Do not withhold EV+P based solely on age—functional status and organ function matter more 1
2. Do not use single-agent chemotherapy in fit elderly patients—combination therapy shows survival advantage in ages 70-89 5, 6
3. Do not continue treatment through progressive toxicity without dose modification—70% of octogenarians require dose reduction 3
4. Do not assume all elderly patients can tolerate EV+P—assess social support and ability to manage complex toxicity profiles 7